KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results

(NASDAQ:KALA) KALA BIO, Inc. announced preliminary unaudited financial results for the quarter ended September 30, 2026. The company reported a net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025. For the nine months ended September 30, 2026, KALA reported a net loss of approximately $4.0 million, compared to $27.7 million for the same period in 2025. As of September 30, 2026, KALA had cash, cash equivalents, and short-term investments totaling approximately $7.0 million, with no debt. Avi Minkowitz, Chief Executive Officer and Chief Financial Officer, stated that the company reduced its quarterly net loss by approximately 90% year over year and continues to develop its ongoing initiatives. The company thanked its stockholders who attended the Annual Meeting on November 3, 2026. KALA expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, with the SEC on or about November 16, 2026. The results disclosed are preliminary, unaudited, and subject to completion of financial close procedures and review by the company's independent registered public accounting firm. Final results to be included in the Form 10-Q may differ from these preliminary figures. KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company operates a dual strategy combining a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates, with a scalable AI platform-as-a-service business. KALA holds an exclusive worldwide license for the Researgency AI research platform from Younet. The company is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. KALA's focus includes enterprise security, real-time performance, and seamless integration for life sciences AI applications.